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Background: Tobacco smoking and diabetes mellitus contribute significantly to the overall health burden and 
mortality of Australians. We aimed to assess the relationship of smoking with glycemic control, metabolic profile 
and complications in Australian patients living with diabetes. 
Methods: We analysed the 2011-2017 biennial Australian National Diabetes Audit cross-sectional data. Patients 
were classified as current, past or never smokers. Linear (or quantile) and logistic regression models were used to 
assess for associations.  
Results: Data from 15,352 patients were analysed, including 72.2% with type 2 diabetes. Current smokers 
comprised 13.5% of the study population. Current and past smokers had a median HbA1c that was 0.49% and 
0.14% higher than never smokers, respectively, as well as higher triglyceride and lower HDL levels (p <0.0001 for 
all). Compared to never smokers, current smokers had higher odds of severe hypoglycaemia and current and past 
smokers had higher odds of myocardial infarction, stroke, peripheral vascular disease, lower limb amputation, 
erectile dysfunction and peripheral neuropathy (all p values ≤0.001), with no significant change over time. 
Conclusion: When compared to never smokers, current and past smokers had poorer glycemic and lipid control 
and higher odds of macrovascular and microvascular complications. Despite this, current smoking remains 
prevalent among Australians with diabetes.  
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Diabetes mellitus is a major public health challenge in Australia. An estimated 1.2 million (6%) Australian adults 
are affected by diabetes, with approximately 85% representing type 2 diabetes (T2DM) and 10% with type 1 
diabetes (T1DM).1, 2 In 2015 diabetes was estimated to contribute to over 1 million hospitalisations per year and 
10% of all deaths in Australia.2, 3 Diabetes also places a substantial economic burden on the Australian population, 
with over $14.5 billion dollars spent on diabetes-related health expenditure annually.4 
 
Tobacco smoking was estimated to be responsible for 9.3% of the disease burden in Australia in 2015; the leading 
risk factor for both chronic disease and death. In Australia in 2015 it was estimated that smoking contributed to 
almost 21,000 deaths (13.3% of all deaths), with the most common underlying causes of death being chronic 
obstructive pulmonary disease, lung cancer, coronary heart disease and stroke.5 Globally, smoking contributed to 
over seven million deaths in 2017.6 
 
Nicotine deleteriously alters glucose homeostasis through a number of mechanisms, including impaired β cell 
function, increased insulin resistance7-9 and hormonally-mediated hyperglycaemia10, 11. As such, tobacco smoking 
has been causally linked with an increased risk of developing type 2 diabetes, which has been observed in a dose-
dependent manner and seen in both active and passive smoking7, 12, 13. The 2014 Surgeon General’s report on the 
health consequences of smoking, estimated the risk of developing diabetes to be 30-40% higher in smokers than 
in never smokers.14 This increased risk was reported to be abrogated or reversed by smoking cessation, such that 
long-term quitters (>10 years) have a risk almost equivalent to that of the general population.14, 15 People with 
diabetes who smoke have worse glycemic control than non-smokers. This may manifest as either hyperglycaemia 
and its associated complications, with a substantially increased risk of cardiovascular disease (up to 50% greater 





Guidelines impress the importance of both promoting smoking cessation as a key public health issue in order to 
control the ever-expanding epidemic of diabetes worldwide,14 and also as an essential standard of care in the 
management of people with diabetes.15, 16, 18 However, efforts to understand contemporary rates of smoking 
among people with diabetes in Australia and the relationship between smoking and complications, have not yet 
been reported. 
 
In this study, we aimed to examine the association of smoking status with glycemic control, metabolic profile and 
diabetic complications among over 15,000 adults living with diabetes in Australia, and to monitor the change in 




2.1 Study design, setting and patients 
We conducted an observational, cross-sectional study using the Australian National Diabetes Audit (ANDA) data. 
ANDA is an annual, de-identified, cross-sectional audit performed by over 50 primary, secondary and tertiary 
health care services throughout Australia. It is facilitated by the National Association of Diabetes Centre (NADC) – 
a division of the Australian Diabetes Society, with funding provided by the Australian Government Department of 
Health and Ageing. The data provide both Australian-wide and facility specific information on diabetes 
management, diabetes complications and the overall wellbeing of patients who are attending diabetes services 
across every state and territory in Australia. The audit aims to deliver an important basis for quality improvement 




ANDA involves data collection over a four-week period in May to June each year, with an alternating biennial 
focus on either self-management and quality of life (Australian Quality Self-Management Audit – AQSMA) or 
clinical management indicators (Australian Quality Clinical Audit – AQCA). In brief, participation is voluntary and 
formal invitations to participate are sent to all centres registered with the NADC and other interested primary 
care, community-based or specialist healthcare providers in private practice. Unique site codes are allocated to 
allow data collection, handling and analysis to be undertaken in a double-blind fashion. Over four weeks (either 
during May or June) clinicians complete either an electronic or hard copy data collection form for all consecutive 
patients reviewed at a participating centre. Data were collected during the standard medical consultation by the 
treating health professional who reviewed medical records and available pathology, in discussion with the 
patient.20 The data collection form involves a single page minimal dataset including patient demographics, 
diabetes history and management, anthropometric measurements, comorbidities and diabetic complications 
(Supplementary Figure 1).  
 
For the purposes of this study, data were pooled from four consecutive biennial ANDA-AQCA audits: 2011, 2013, 
2015 and 2017. All adults with type 1 diabetes, type 2 diabetes and diabetes due to unknown or other aetiologies 
were included in this study. Those with gestational diabetes and those aged under 18 years were excluded. Given 
the focus of the effect of smoking in this study, those without information regarding smoking status were 
excluded. 
 
Ethics approval for our study was provided by the Monash Health Human Research Ethics Committee (Monash 
Health Reference: RES-17-0000-164L). 
 
2.2 Dependent variable 
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The pre-specified dependent variable was self-reported smoking status – with never smokers including patients 
who reported never smoking regularly for longer than a one-month period, past smokers including patients who 
reported no regular smoking in the preceding one month and current smokers including patients who reported 
regular smoking. 
 
2.3 Independent variables 
Pre-specified independent variables included glycemic control (glycated haemoglobin - HbA1c (%), severe 
hypoglycaemia (yes if reported having ever had an episode of severe hypoglycaemia requiring the assistance of 
another person) and number of therapeutics), microvascular complications (retinopathy, peripheral neuropathy, 
advanced chronic kidney disease (CKD), microalbuminuria, macroalbuminuria and erectile dysfunction), 
macrovascular complications (peripheral vascular disease, myocardial infarction, coronary artery 
revascularisation, cerebral stroke, foot ulceration and lower limb amputation), body mass index (BMI) and blood 
pressure (systolic and diastolic blood pressure).  
 
The most recent pathology results from patients were recorded and included HbA1c (% or mmol/mol), serum 
creatinine (µmol/L) and lipid profile (total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL) 
and triglycerides – all mmol/L – including both fasting and non-fasting values, depending on availability. Given the 
large number of services that provided the pathology collected, laboratory values across centres were not able to 
be standardised. An estimated glomerular filtration rate (eGFR) was calculated using age, sex and serum 
creatinine as per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (Supplementary 1).21  
 
Advanced CKD was defined as present if either the calculated eGFR was <30mL/min/1.73m2; representing stage 4 
to 5 CKD, or if the patient had a history of renal replacement therapy or renal transplantation as recorded on the 
data collection form. The most recent urine collection examining protein or albumin was recorded. The urine 
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albumin result was used to derive the presence of microalbuminuria or macroalbuminuria.22 Systolic and diastolic 
blood pressures were recorded at the time of appointment in mmHg. BMI (kilogram/metre2) was calculated using 
measured weight (kg) and height (m) and the formula: weight / (height x height). 
 
The number of glucose lowering therapies was reported in those with type 2 diabetes only, and calculated as the 
total number of prescribed medications from the following classes; Insulin, Acarbose, Glucagon like peptide 1 
(GLP-1) receptor agonist, Glitazone, Sulphonylurea, Metformin, Dipeptidyl peptidase-4 (DPP-4) inhibitor and 
Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors. 
 
Anti-hypertensive therapy use was reported if any medications from the following classes were prescribed; 
angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), beta blocker, thiazide, 
calcium channel blocker or other anti-hypertensive agent. Lipid lowering therapy use was reported if any 
medications from the following classes were prescribed; statin, fibrate, ezetimibe or fish oil. 
 
Microvascular and macrovascular complications were recorded as present if the patient reported having ever had 
the disease following direct questioning, or if it was documented as part of their past medical history. Presence of 
retinopathy, peripheral neuropathy, advanced CKD, erectile dysfunction (males only), peripheral vascular disease, 
myocardial infarction, coronary artery revascularisation (coronary artery bypass graft surgery 
(CABG)/angioplasty), cerebral stroke, foot ulceration and lower limb amputation was recorded by the treating 
specialist at the time of data collection.  
 
2.4 Confounding variables 
Pre-specified confounding variables included age (years), sex (male and female), diabetes type (type 1, type 2 and 




2.5 Statistical analysis 
Patients were categorised by smoking status: never smoker, past smoker or current smoker, and summarised 
descriptively for the pooled cohort. Categorical variables were presented as percentages and counts (n), and 
differences in subgroups were analysed using the Chi-square test. Continuous variables were presented as mean 
(standard deviation) or median (interquartile range (IQR)), and differences in subgroups analysed using Analysis of 
Variance (ANOVA – for normally distributed data) and Kruskal-Wallis test (for skewed data).  Missing data were 
minimal for most variables, and below the selected cut-off of no more than 20% for the dependent variable. 
Certain variables that required pre-performed investigations, had a higher level of missing data. No imputation 
was performed. Data regarding SGLT2 inhibitors were not available in 2011 and 2013 audits (the data collection 
form is reviewed and updated each year for novel treatments).  
 
Quantile (median) regression was used for non-normally distributed continuous outcome variables; HbA1c, BMI, 
total cholesterol, LDL, HDL and triglycerides, and unadjusted and adjusted median differences were reported. 
Ordinal regression was used to assess the relationship between smoking status and the number of therapies, and 
unadjusted and adjusted Odds Ratios were reported. Linear regression was used for normally distributed 
continuous outcome variables; systolic and diastolic blood pressure, and unadjusted and adjusted mean 
differences were reported. Binary logistic regression was used to explore the relationship between smoking status 
and binary outcome variables: severe hypoglycaemia, retinopathy, peripheral neuropathy, advanced CKD, 
microalbuminuria, macroalbuminuria, erectile dysfunction, peripheral vascular disease, myocardial infarction, 
coronary artery revascularisation, stroke, foot ulceration, lower limb amputation, use of anti-hypertensive 
therapy and use of lipid lowering therapy, and unadjusted and adjusted Odds Ratios were reported.  Multivariable 
models were performed for each outcome, adjusted for age, sex, diabetes type, diabetes duration and year of 
data collection; as these variables were determined a-priori to be clinically important confounders. The 
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moderating effect of year of data collection was examined by including an interaction term between year and 
smoking on each outcome, and the likelihood ratio test was used to evaluate whether the inclusion of this term 
improved fit of the model. Due to the substantial number of outcome variables and to avoid the issue of 
multiplicity, a more stringent level of significance (p <0.002) was used to determine statistical significance, using 
the Bonferroni method.  All analyses were performed in Stata Statistical Software (StataCorp, College Station, 




3.1 Descriptive Summary 
Data from 19,374 patients were reviewed from the 2011, 2013, 2015 and 2017 ANDA-AQCA audits. Of those, 
15,352 patients had a valid smoking status and were included in the analysis for this study. Characteristics of 
study patients are presented in Table 1. Median [IQR] age was 59.9 [46.6, 69.6] and males represented 53.2% of 
patients. The median [IQR] duration of diabetes was 13 [6, 21] years. The largest proportion of patients (72.2%) 
had type 2 diabetes. Current and past smokers represented 46.3% of the study population. The median number 
and type of glucose lowering therapies including insulin was broadly similar among the smoking categories. 
Compared to never and past smokers, current smokers were less likely to report receiving antihypertensive and 
lipid lowering therapy (p<0.0001 for both).   
 
The most frequently reported complications were erectile dysfunction among men (29.5%), microalbuminuria 
(28.4%), peripheral neuropathy (24.9%) and retinopathy (22.1%). The proportion of patients with complications 
(i.e. peripheral neuropathy, microalbuminuria, macroalbuminuria, erectile dysfunction, peripheral vascular 
disease, myocardial infarction, coronary artery revascularisation, stroke, foot ulcer, lower limb amputation and 




Table 1: Characteristics of patients participating in the Australian National Diabetes Audit (2011, 
2013, 2015 and 2017), stratified by smoking status 





















Age (years) α 59.9 [46.6, 69.6] 59.1 [42.9, 69.7] 63.7 [54.3, 71.4] 52.7 [41.8, 62.2] 0.0001 
Sex (male) 53.2 (8,111) 43.2 (3,533) 67.0 (3,350) 59.6 (1,228) <0.0001 
Diabetes type     <0.0001 
Type 1 24.8 (3,804) 28.2 (2,325) 17.1 (861) 29.7 (618)  
Type 2 72.2 (11,087) 68.7 (5,665) 80.2 (4,034) 66.8 (1,388)  
Other 3.0 (461) 3.1 (251) 2.7 (138) 3.5 (72)  
Diabetes duration α 13 [6, 21] 13 [7, 21] 14 [7, 21] 10 [4, 18] 0.0001 
Diabetes therapeutics 
type 
    <0.0001 
Diet only 3.6 (552) 3.8 (316) 3.4 (169) 3.2 (67)  
 Tablets and non-insulin 
injectables only 
23.7 (3,638) 23.4 (1,931) 24.1 (1,212) 23.8 (495)  
Insulin only 36.5 (5,605) 39.4 (3,245) 30.8 (1,549) 39.0 (811)  
Tablets + insulin 30.9 (4,744) 28.3 (2,332) 36.2 (1,822) 28.4 (590)  
Other/unstated 5.3 (813) 5.1 (417) 5.6 (281) 5.5 (115)  
Insulin-treated 70.6 (10,675) 70.8 (5,740) 70.3 (3,489) 70.4 (1,446) 0.803 
Insulin duration (years) α* 7 [2, 15] 8 [3, 15] 6 [2, 15] 6 [2, 15] 0.0001 
Glycemic control      
HbA1c (%) α 7.9 [7.0, 9.0] 7.8 [6.9, 8.9] 7.9 [7.0, 9.0] 8.4 [7.2, 9.7] 0.0001 
Severe hypoglycaemia 8.7 (1,286) 8.3 (654) 8.8 (425) 10.4 (207) 0.010 
Number of glucose lowering 
therapies α± 
2 [1, 2] 2 [1, 2] 2 [1, 2] 2 [1, 2] 0.156 
BMI α 30.4 [26.2, 35.5] 29.8 [25.7, 34.9] 31.7 [27.5, 36.7] 29 [24.7, 34.6] 0.0001 
Complications       
Retinopathy 22.1 (2,886) 21.5 (1,520) 24.3 (1,043) 19.0 (323) <0.0001 
Peripheral neuropathy  24.9 (3,761) 21.2 (1,721) 31.1 (1,543) 24.4 (497) <0.0001 
Advanced CKD 7.4 (1,092) 7.0 (556) 9.1 (442) 4.7 (94) <0.0001 
Microalbuminuria 28.4 (2,737) 26.4 (1,387) 31.8 (1,004) 28.5 (346) <0.0001 
Macroalbuminuria 12.9 (1,242) 11.1 (583) 14.7 (466) 15.9 (193) <0.0001 
Erectile dysfunction× 29.5 (2,220) 24.5 (814) 35.8 (1,106) 27.0 (300) <0.0001 
Peripheral vascular disease 11.0 (1,649) 7.7 (624) 15.5 (766) 12.8 (259) <0.0001 
Myocardial infarction 12.4 (1,820) 8.8 (692) 18.6 (903) 11.3 (225) <0.0001 
Coronary artery 
revascularisation 
13.1 (1,936) 9.7 (771) 20.0 (981) 9.4 (184) <0.0001 
Stroke  6.2 (925) 5.1 (407) 8.3 (405) 5.6 (113) <0.0001 
Foot ulcer 8.2 (1,215) 6.6 (520) 10.6 (516) 9.0 (179) <0.0001 
Lower limb amputation 3.0 (443) 2.2 (178) 4.0 (195) 3.5 (70) <0.0001 
Lipids      
Cholesterol α 4.2 [3.5, 5.0] 4.2 [3.6, 5.0] 4.0 [3.4, 4.8] 4.4 [3.6, 5.3] 0.0001 
LDL α 2.1 [1.6, 2.8] 2.1 [1.6, 2.8] 2.0 [1.5, 2.6] 2.3 [1.7, 2.9] 0.0001 
HDL α 1.1 [0.9, 1.4] 1.2 [1.0, 1.5] 1.1 [0.9, 1.4] 1.1 [0.9. 1.3] 0.0001 
Triglycerides α 1.6 [1.0, 2.4] 1.5 [1.0, 2.2] 1.7 [1.1, 2.5] 1.7 [1.1, 2.7] 0.0001 
Blood pressure       
Systolic BP β 130.8 (±17.9) 130.3 (±17.9) 132.5 (±17.9) 128.2 (±17.9) 0.980 
Diastolic BP β 74.8 (±10.7) 74.7 (±10.6) 74.6 (±10.7) 75.7 (±11.0) 0.075 
      
Antihypertensive therapy 64.7 (9,501) 60.8 (4,779) 75.4 (3,650) 54.2 (1,072) <0.0001 
Lipid lowering therapy 64.7 (9,657) 60.8 (4,851) 74.1 (3,648) 57.5 (1,158) <0.0001 
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*Insulin duration and SGLT2 inhibitor use were not available for 2011 and 2013 data. α median [interquartile range] reported, 
differences analysed with Kruskal Wallis test. β mean (standard deviation) reported, differences analysed with ANOVA. Number of 
treatments (±) includes the total number of medication classes of: insulin, acarbose GLP-1 agonist, glitazone, sulphonylurea, 
metformin, DPP-4 inhibitor and SGLT2 inhibitor in those with type 2 diabetes only. ×data collected and analysed in males only. 
 
 
3.2 The association between smoking status and clinical outcomes 
The results of unadjusted and adjusted analyses (for age, sex, diabetes type, diabetes duration and study year) 
examining the relationship of smoking status with glycemic control, metabolic profile and microvascular and 
macrovascular complications are presented in Table 2, Figure 1 and Figure 2.  
 
 
Table 2: The association of smoking status with glycemic and metabolic outcomes in Australian 
patients living with diabetes  





































HbA1c (%) 0.10 [0.03, 
0.17] 

















































































































































































































































































           
Reference category is non-smokers. Adjusted for age (continuous), sex (male or female), diabetes type (type 1, type 2, other), diabetes 
duration (years) and year (2011, 2013, 2015, 2017) 
p-values significance set at 0.05/22(outcomes) = 0.002 
 
3.3 Glycemic and Metabolic Profile 
The median HbA1c was 0.49% higher among current smokers (median difference 0.49, [0.40, 0.59], p <0.0001), 
and 0.14% higher among past smokers (0.14, [0.07, 0.21], p <0.0001) when compared to never smokers.  There 
was no relationship between smoking status and the number of glucose lowering therapies used.  Current 
smokers (aOR=1.49 [1.25, 1.78], p <0.0001) had higher odds of severe hypoglycaemia than never smokers. 
 
Current smokers had a lower median BMI (-0.78 [-1.18, -0.37], p <0.0001) and past smokers had a higher median 
BMI (1.57 [1.27, 1.87], p <0.0001) than never smokers. Total cholesterol, LDL cholesterol and systolic and diastolic 
blood pressure differences between smoking groups were not significant.  HDL cholesterol levels were 0.08 
mmol/L (-0.08, [-0.11, -0.06], p <0.0001) lower in current smokers and 0.04 mmol/L (-0.04, [-0.05, -0.02], p 
<0.0001) lower in past smokers, compared to never smokers. Triglyceride levels were 0.26 mmol/L (0.26, [0.20, 
0.32], p <0.0001) higher in current smokers and 0.12 mmol/L (0.12 [0.08, 0.16], p <0.0001) higher in past 




Insert figures 1 and 2 in this area. 
 
3.4 Microvascular complications 
Compared to never smokers, the odds of peripheral neuropathy were higher in current (aOR=1.54 [1.36, 1.74], p 
<0.0001) and past smokers (aOR=1.38 [1.26, 1.51], p <0.0001). The odds of macroalbuminuria (aOR=1.53 [1.28, 
1.84], p <0.0001) were also higher in current compared to never smokers. Smoking status was not significantly 
associated with retinopathy, microalbuminuria and advanced CKD.  
 
3.5 Macrovascular complications 
Current and past smokers had higher odds of myocardial infarction (aOR=1.74 [1.47, 2.06] and aOR=1.76 [1.57, 
1.98]), cerebral stroke (aOR=1.47 [1.18, 1.85] and aOR=1.35 [1.16, 1.57]) and peripheral vascular disease 
(aOR=2.50 [2.11, 3.00] and aOR=1.75 [1.55, 1.97]), when compared to never smokers (all p <0.001). In addition, 
past smokers (aOR=1.70 [1.53, 1.91], p <0.0001) had higher odds of having undergone coronary artery 
revascularisation procedures, when compared to never smokers.  
 
3.6 Other complications 
Both current and past smokers had higher odds of foot ulceration (aOR=1.59 [1.32, 1.91] and aOR=1.36 [1.19, 
1.55]), lower limb amputation (aOR=1.73 [1.28, 2.33] and aOR=1.42 [1.14, 1.78]) and erectile dysfunction 
(aOR=1.49 [1.26, 1.76] and aOR=1.37 [1.22, 1.53]) when compared to never smokers (all p <0.0001).  
 
3.7 Annual trends (effect of study year) 
The association of smoking status with glycemic control, metabolic risk factors and diabetic complications did not 






We explored the association between smoking status and glycemic control, metabolic risk factors and 
microvascular and macrovascular complications in over 15,000 Australian adults living with diabetes. We 
observed that current smoking was associated with worse glycemic control as demonstrated by a higher median 
HbA1c and higher odds of severe hypoglycaemia, despite this sub-group being on average younger and having had 
diabetes for a shorter period of time. Current and past smoking were also associated with higher odds of 
dyslipidaemia, peripheral neuropathy, erectile dysfunction, peripheral vascular disease, myocardial infarction, 
cerebral stroke, foot ulceration and lower limb amputation. The odds associated with current and past smoking 
were considerably higher for macrovascular, compared with microvascular complications.  
 
The results of our study are consistent with the growing evidence on the detrimental effects of smoking in 
diabetes.14, 16, 23, 24 Similarly, the long-standing associations seen between smoking and micro- and macrovascular 
complications25-27 have also been reported in more recent literature.28-31 We build on this evidence by also 
reporting a significant association between current smoking and worse glycemic control and metabolic profile and 
an increased risk of a range of diabetic complications including severe hypoglycaemia, among a large group of 
patients attending diabetes centres across Australia. 
 
We observed that the prevalence of smoking in our cohort with diabetes (13.5%) was similar to that among the 
general Australian population (13.8%) in 2017-18.1 This suggests suboptimal adherence to primary and/or 
secondary prevention recommendations on smoking cessation in this high-risk population. Furthermore, the 
potential for weight gain in the initial period of smoking cessation32 should not deter patients from making efforts 
given the substantial improvements in metabolic parameters,33 and the lower risk of microvascular and 
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macrovascular complications and mortality34 that accompany smoking cessation.  Given the ongoing high rates of 
smoking, assessment of tobacco use and counselling or treatments that aid smoking cessation, as recommended 
by guidelines, should be considered as an imperative for improving outcomes among people with diabetes.15, 18 
Further research on interventions that promote smoking cessation among people with diabetes would also be 
useful. 
 
Among current smokers, treatment with antihypertensive and lipid lowering therapy was significantly lower, 
whilst use of glucose lowering therapies was similar, compared to past and never smokers, despite their greater 
risk profile. This highlights the need for continued review and re-evaluation of clinical guidelines and optimal 
patient-specific targets, so that timely intensification of therapy occurs and clinical inertia is avoided.15, 35 
  
A strength of the use of the ANDA data is that it provides information regarding a large population of patients 
with both type 1 and type 2 diabetes, throughout all states and territories of Australia. We believe these data 
describe for the first time the prevalence of smoking and its relationship with diabetic outcomes among an 
Australian population of individuals with diabetes. There are limitations to the use of the ANDA dataset. All data 
collected are cross-sectional in nature with no current linked follow up of the de-identified patients from one 
audit to another. In that setting, we are able to only discuss associations rather than causal interactions, and there 
is also no capacity to collect mortality data. However, there is scope to add linked longer-term assessments in 
future years, with the addition of a longitudinal component to the audit that will be commencing with the 2019 
ANDA AQCA data collection. There was a high prevalence of missing data for the albumin and lipid profile 
variables, therefore these variables should be interpreted with caution as a larger proportion of participants were 
excluded from their analysis, which has the potential to introduce selection bias for these outcomes. Another 
limitation is that a larger proportion of patients are from tertiary diabetes services rather than primary care 
practices, which may also introduce referral bias. More complicated patients with multiple complications tend to 
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be referred for further specialist management, therefore our cohort may not be entirely comparable to the 
population with diabetes that is managed in general practice. There is also reliance on the patient or the 
healthcare worker to accurately complete the data collection form, as the de-identified data cannot be further 




In an adult Australian population of patients with diabetes, current and past smoking was associated with worse 
glycemic and lipid control, and higher odds of macrovascular and microvascular complications, when compared to 
never smoking. The prevalence of complications has not improved over recent years, even with the introduction 
of newer therapeutic agents. Despite this increased risk, smoking remains prevalent among the diabetic 
population. Smoking cessation should be a major focus of care among people with diabetes. This, together with 
addressing physician- patient- and healthcare-related factors that contribute to lack of timely initiation and 
intensification of appropriate treatment, may help improve glycemic and metabolic control and prevent or halt 













ACE – Angiotensin-Converting Enzyme 
ARB – Angiotensin II Receptor Blocker 
ANDA – Australian National Diabetes Audit 
ANOVA – Analysis of Variance 
aOR – Adjusted Odds Ratio 
AQCA – Australian Quality Clinical Audit 
AQSMA – Australian Quality Self-Management Audit 
BMI – Body Mass Index 
BP – Blood Pressure 
CABG – Coronary Artery Bypass Graft 
CKD – Chronic Kidney Disease 
CKD-EPI – Chronic Kidney Disease Epidemiology Collaboration 
DDP-4 – Dipeptidyl Peptidase-4 
eGFR – Estimated Glomerular Filtration Rate 
ESKD – End Stage Kidney Disease 
GLP-1 – Glucagon Like Peptide 1 
HbA1c – Haemoglobin A1C 
HDL – High Density Lipoprotein 
IQR – Interquartile Range 
LDL – Low Density Lipoprotein 
NADC – National Association of Diabetes Centre 
SGLT2 – Sodium-Glucose Co-Transporter 2 
T1DM – Type 1 Diabetes Mellitus 
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Supplementary 1: eGFR formula 
eGFR (mL/min/1.73m2) = 175 x [Serum Creatinine (μmol/L) x 0.0113] - 1.154 x Age(years) - 0.203 (x 
0.742 if female) 
 
Supplementary Table 1: Missing Data Table 
   
Number missing 
(of total, 15,352) 
Percentage 
(%) 
Smoking status 0 0 
Age 56 0.4 
Sex 118 0.8 
Diabetes type 0 0 
Diabetes duration  203 1.3 
Diabetes therapy 74 0.5 
Insulin therapy 230 1.5 
Insulin duration  2,863(/10,675) 26.8 
HbA1c (%) α 1,077 7.0 
Severe hypoglycaemia 624 4.1 
Number of Glucose Lowering 
Therapies 
71 0.5 
BMI 1,167 7.6 
Retinopathy 2,294 15.0 
Peripheral neuropathy  227 1.5 
Advanced CKD 536 3.5 
Microalbuminuria 5,717 37.2 
Macroalbuminuria 5,717 37.2 
Erectile dysfunction 690 (/8,111) 8.5 
Peripheral vascular dis. 286 1.9 




Stroke  513 3.4 
Foot ulceration 604 3.9 
Lower limb amputation 539 3.5 
Cholesterol α 3,624 23.6 
LDL α 5,615 36.6 
HDL α 5,214 33.9 
Triglycerides α 3,927 25.6 
Systolic BP 412 2.7 
Diastolic BP 413 2.7 
Antihypertensive therapy 668 4.4 
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